These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32795681)

  • 1. Novel therapeutic approaches for the treatment of achondroplasia.
    Legeai-Mallet L; Savarirayan R
    Bone; 2020 Dec; 141():115579. PubMed ID: 32795681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis.
    Chen L; Adar R; Yang X; Monsonego EO; Li C; Hauschka PV; Yayon A; Deng CX
    J Clin Invest; 1999 Dec; 104(11):1517-25. PubMed ID: 10587515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
    Webster MK; Donoghue DJ
    EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.
    Aviezer D; Golembo M; Yayon A
    Curr Drug Targets; 2003 Jul; 4(5):353-65. PubMed ID: 12816345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
    Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
    Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia.
    Chen L; Li C; Qiao W; Xu X; Deng C
    Hum Mol Genet; 2001 Mar; 10(5):457-65. PubMed ID: 11181569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
    Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
    Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR3 targeting strategies for achondroplasia.
    Laederich MB; Horton WA
    Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fibroblast growth factor receptor and achondroplasia].
    Tanaka H
    Clin Calcium; 2006 Nov; 16(11):1888-93. PubMed ID: 17079857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achondroplasia: pathogenesis and implications for future treatment.
    Laederich MB; Horton WA
    Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.
    Wang Y; Spatz MK; Kannan K; Hayk H; Avivi A; Gorivodsky M; Pines M; Yayon A; Lonai P; Givol D
    Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4455-60. PubMed ID: 10200283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achondroplasia: Development, pathogenesis, and therapy.
    Ornitz DM; Legeai-Mallet L
    Dev Dyn; 2017 Apr; 246(4):291-309. PubMed ID: 27987249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
    Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
    Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Naski MC; Wang Q; Xu J; Ornitz DM
    Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular defects in achondroplasia and the effects of growth hormone treatment.
    Seino Y; Moriwake T; Tanaka H; Inoue M; Kanzaki S; Tanaka T; Matsuo N; Niimi H
    Acta Paediatr Suppl; 1999 Feb; 88(428):118-20. PubMed ID: 10102070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
    van Ravenswaaij-Arts CM; Losekoot M
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
    Legeai-Mallet L
    Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
    Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
    Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia.
    Stoilov I; Kilpatrick MW; Tsipouras P
    Am J Med Genet; 1995 Jan; 55(1):127-33. PubMed ID: 7702086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism.
    Bonaventure J; Rousseau F; Legeai-Mallet L; Le Merrer M; Munnich A; Maroteaux P
    Am J Med Genet; 1996 May; 63(1):148-54. PubMed ID: 8723101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.